title: Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel.
abstract: Afatinib is an irreversible ErbB family blocker tyrosine kinase inhibitor (TKI), which has recently been approved for the treatment of patients with EGFR M+ non-small cell lung cancer. As observed with reversible EGFR TKIs, it can induce class-effect adverse events. Appropriate management of afatinib-related adverse events improves quality of life and clinical outcomes in these patients. Here we provide practical recommendations for the prophylaxis and treatment of the most common of these (e.g., diarrhea, rash, mucositis and others).
authors.affiliation: Department of Medical Oncology, Hospital del Mar, Passeig Marítim 25-29, 08003 Barcelona; IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Dr Aiguader 88, 08003 Barcelona, Spain.
authors.forename: Edurne
authors.initials: E
authors.lastname: Arriola
authors.forename: Noemi
authors.initials: N
authors.lastname: Reguart
authors.forename: Angel
authors.initials: A
authors.lastname: Artal
authors.forename: Manuel
authors.initials: M
authors.lastname: Cobo
authors.forename: Rosario
authors.initials: R
authors.lastname: García-Campelo
authors.forename: Emilio
authors.initials: E
authors.lastname: Esteban
authors.forename: Mari Carmen
authors.initials: MC
authors.lastname: Rodríguez
authors.forename: Maria Pilar
authors.initials: MP
authors.lastname: García-Muret
mesh_terms: D000077716:Afatinib; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003967:Diarrhea / Q000139:chemically induced / Q000628:therapy; D019468:Disease Management; D005076:Exanthema / Q000139:chemically induced / Q000628:therapy; D006801:Humans; D052016:Mucositis / Q000139:chemically induced / Q000628:therapy; D009369:Neoplasms / Q000188:drug therapy*; D010304:Paronychia / Q000139:chemically induced / Q000628:therapy; D017410:Practice Guidelines as Topic; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D013030:Spain; D013280:Stomatitis / Q000139:chemically induced / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077716:Afatinib
keywords: Del19; EGFR; L858R; adverse events; afatinib; mutation; non-small lung cancer